Screener
Vaxcyte, Inc. PCVX Operating Income
Operating Income at other companies
Other financials
Where this comes from
Reported directly by Vaxcyte, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The source filing: Vaxcyte, Inc.’s 10-Q, filed May 6, 2026.
- Filed
- May 6, 2026, 4:12 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001649094-26-000017
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Research and development | $312,779 | $148,134 |
| General and administrative | 33,071 | 32,659 |
| Total operating expenses | 345,850 | 180,793 |
| Loss from operations | (345,850) | (180,793) |
| Other income, net: | ||
| Interest income | 26,610 | 32,935 |
| Other income (expense) | (1,382) | 7,140 |
| Total other income, net | 25,228 | 40,075 |
Item 1. Condensed Consolidated Financial Statements (unaudited)
FAQ
- What is Vaxcyte, Inc.'s operating income?
- Vaxcyte, Inc. (PCVX) reported operating income of -$345.85M in Q1 2026.
- How has Vaxcyte, Inc.'s operating income changed year-over-year?
- Vaxcyte, Inc.'s operating income decreased by 91.3% year-over-year, from -$180.79M to -$345.85M.
- What is the long-term trend for Vaxcyte, Inc.'s operating income?
- Over 4 years (2021 to 2025), Vaxcyte, Inc.'s operating income has grown at a 72.8% compound annual growth rate (CAGR), from -$103.67M to -$923.68M.
- What does operating income mean?
- Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.
Ask your AI about Vaxcyte, Inc.'s operating income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude